Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC trial in CIDP
NL-OMON50340Phase 3Suspended
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing IVIg + intravenous methylprednisolone with IVIg + placebo (2 arms). Primary endpoint: Remission at 1 year after start of 18-week treatment period. Started Feb 2018; status: suspended.
02
Drugs
immune globulinmethylprednisolone
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON50340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50340.